InnoCare Pharma Limited (9969.HK)

HKD 10.44

(2.76%)

Long Term Debt Summary of InnoCare Pharma Limited

InnoCare Pharma Limited's latest annual long term debt in 2023 was 69.94 Million CNY , up 97.37% from previous year.
InnoCare Pharma Limited's latest quarterly long term debt in 2024 Q2 was 73.68 Million CNY , up 2.42% from previous quarter.
InnoCare Pharma Limited reported annual long term debt of 35.43 Million CNY in 2022, down -97.16% from previous year.
InnoCare Pharma Limited reported annual long term debt of 1.24 Billion CNY in 2021, up 6.97% from previous year.
InnoCare Pharma Limited reported quarterly long term debt of 68.76 Million CNY for 2024 Q1, up 25.86% from previous quarter.
InnoCare Pharma Limited reported quarterly long term debt of 321.79 Million CNY for 2023 Q1, up 808.02% from previous quarter.

Annual Long Term Debt Chart of InnoCare Pharma Limited (2023 - 2017)

Historical Annual Long Term Debt of InnoCare Pharma Limited (2023 - 2017)

Year	Long Term Debt	Long Term Debt Growth
2023	69.94 Million CNY	97.37%
2022	35.43 Million CNY	-97.16%
2021	1.24 Billion CNY	6.97%
2020	1.16 Billion CNY	4.12%
2019	1.12 Billion CNY	16.11%
2018	965.06 Million CNY	1584.72%
2017	57.28 Million CNY	0.0%

Year	Long Term Debt	Long Term Debt Growth
2024 Q2	73.68 Million CNY	2.42%
2024 Q1	68.76 Million CNY	25.86%
2023 Q1	321.79 Million CNY	808.02%
2023 FY	69.94 Million CNY	97.37%
2023 Q3	48.29 Million CNY	12.67%
2023 Q2	42.86 Million CNY	-86.68%
2023 Q4	69.94 Million CNY	44.83%
2022 Q4	35.43 Million CNY	-88.97%
2022 Q3	321.16 Million CNY	-74.51%
2022 Q2	1.26 Billion CNY	0.0%
2022 Q1	- CNY	-100.0%
2022 FY	35.43 Million CNY	-97.16%
2021 Q4	1.24 Billion CNY	0.0%
2021 FY	1.24 Billion CNY	6.97%
2021 Q1	1.22 Billion CNY	5.29%
2021 Q2	1.22 Billion CNY	0.0%
2020 Q4	1.16 Billion CNY	0.0%
2020 Q2	1.15 Billion CNY	0.0%
2020 Q1	1.15 Billion CNY	2.67%
2020 FY	1.16 Billion CNY	4.12%
2020 Q3	1.16 Billion CNY	1.41%
2019 Q1	3.57 Billion CNY	270.17%
2019 FY	1.12 Billion CNY	16.11%
2019 Q3	1 Billion CNY	-71.85%
2019 Q2	3.57 Billion CNY	0.0%
2019 Q4	1.12 Billion CNY	11.44%
2018 FY	965.06 Million CNY	1584.72%
2018 Q4	965.06 Million CNY	0.0%
2017 FY	57.28 Million CNY	0.0%

Peer Long Term Debt Comparison of InnoCare Pharma Limited

Name	Long Term Debt	Long Term Debt Difference
Uni-Bio Science Group Limited	30.61 Million HKD	-128.495%
CK Life Sciences Int'l., (Holdings) Inc.	4.27 Billion HKD	98.363%